ArticleCancer chemotherapy and pharmacology2021

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.

Filipa Lynce et al.PubMed ↗Publisher ↗

No numbers read from the abstract.